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Historical note
EPILEPSY RESEARCH 150 YEARS AFTER 
DARWIN’S THEORY OF EVOLUTION
Fulvio A. Scorza1, Vera C. Terra2, Carla A. Scorza1, Ricardo M. Arida3, Esper A. Cavalheiro1
Abstract – On February 12, 2009, we commemorated the 200th anniversary of Charles Darwin’s birth and 
the 150th anniversary of the publication of the first edition of the “On the origin of species”. Only in the sixth 
edition of the Origin Darwin explicitly stated that natural selection applied to the brain as to all other organs 
and contemporary epilepsy research plays an interesting role in this scenario. Epilepsy affects approximately 
3 percent of the general population and is a complex disease. At least 11 genes have now been described for 
human epilepsy and over 50 more genes have been identified in animal models of epilepsy. The complex gene to 
gene interactions and gene-environment interactions may account for epilepsy susceptibility and antiepileptic 
drug response. Darwin’s thoughts on evolution are relevant to understand these gene interactions, contributing 
to current development of new treatments and prevention of chronic diseases, such as epilepsy.
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Pesquisas em epilepsia 150 anos após a teoria da evolução de Darwin 
Resumo – Em 12 de Fevereiro de 2009 nós comemoramos o aniversário de 200 anos de Charles Darwin e os 
150 anos da publicação da primeira edição do livro “A Origem das Espécies”. Apenas na sexta edição do livro 
A Origem, Darwin explicitamente definiu que a seleção natural se aplicava ao cérebro, assim como a todos 
os outros órgãos e as pesquisas contemporâneas em epilepsia tem um papel interessante neste cenário. 
A epilepsia afeta aproximadamente 3% da população geral e é uma doença complexa. Ao menos 11 genes 
foram descritos até o momento na epilepsia humana e mais de 50 genes foram identificados em modelos 
animais de epilepsia. As complexas interações gene-gene e genes-meio ambiente podem estar relacionadas 
com a susceptibilidade à epilepsia e respostas às drogas antiepilépticas. Os pensamentos de Darwin quanto à 
evolução são relevantes para a compreensão dessas interações gênicas, contribuindo para o desenvolvimento 
de novos tratamentos e na prevenção de doenças crônicas, como a epilepsia.
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On February 12, 2009, we commemorated the 200th 
anniversary of Charles Darwin’s birth (Figure). Charles Rob-
ert Darwin was born on 12 February 1809 in Shrewsbury, 
Shropshire, into a wealthy and well-connected family. He 
was the fifth of six children of wealthy society doctor and 
financier Robert Darwin, and Susannah Darwin. His ma-
ternal grandfather was china manufacturer Josiah Wedg-
wood, while his paternal grandfather was Erasmus Dar-
win, one of the leading intellectuals of 18th century Eng-
land. Darwin himself initially planned to follow a medi-
cal career. He studied at Edinburgh University, but later 
switched to divinity at Cambridge. In 1831, he joined a five-
year scientific expedition on the survey ship HMS Beagle. 
He came up with his fascinating ideas in the Galapagos Is-
lands, 500 miles west of South America1,2. On his return to 
England in 1836, Darwin tried to solve the riddles of these 
observations and the puzzle of how species evolve. He de-
scribed “I can remember the very spot in the road, whilst in 
my carriage, when to my joy the solution occurred to me; 
and this was long after I had come to down. The solution, 
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as I believe, is that the modified offspring of all dominant 
and increasing forms tend to become adapted to many and 
highly diversified places in the economy of nature.” With 
these observations, he proposed a theory of evolution oc-
curring by the process of natural selection. The animals 
and plants best suited to their environment are more like-
ly to survive and reproduce, passing on the characteris-
tics which helped them survive to their offspring. Grad-
ually, the species changes over time. Darwin worked on 
his theory for 20 years and, in 1859, he published “On the 
origin of species”.1-3 Therefore, Darwin expressed his theo-
ry eloquently in 18593: “As many more individuals of each 
species are born than can possibly survive; and as, conse-
quently, there is a frequently recurring struggle for exis-
tence, it follows that any being, if it vary however slightly 
in any manner profitable to itself, under the complex and 
sometimes varying conditions of life, will have a better 
chance of surviving, and thus be naturally selected. From 
the strong principle of inheritance, any selected variety 
will tend to propagate its new and modified form.” So in 
the current year we also celebrate the 150th anniversary of 
the publication of the first edition of the Origin3.
Quite interestingly, Darwin had very little to say 
about the brain in the first edition of the Origin4. A search 
through the digitized version of his work (http://darwin-
online.org.uk) brings up only one mention of the word 
‘brain’, and that is in the context of describing the skull 
and the axial skeleton3,4. The increased focus on the brain 
appeared only in the sixth edition of the Origin, which 
contains a passage explicitly stating that natural selection 
applies to the brain as it does to all the other organs4,5. 
Actually, 150 years after Darwin published the first edition 
of the Origin, we have learned much about how his theory 
of evolution via natural selection is relevant to contem-
porary medicine4. Furthermore, there are several relevant 
evolutionary explanations for diseases nowadays, but one 
of the commonest evolutionary explanations for the or-
igin of human diseases focuses on mismatches between 
genes and the environment6. Along these lines, the con-
temporary epilepsy research also plays an interesting role 
in this scenario. Epilepsy is one of the commonest neuro-
logic problems worldwide7. Approximately 2 million peo-
ple in the United States have epilepsy, and 3 percent of 
the general population will have epilepsy at some point in 
their lives7. Furthermore, it has to be acknowledged that 
more than 80% of people with epilepsy live in developing 
countries, where the condition remains largely untreated8. 
These people could lead normal lives if properly treat-
ed, but the majority of them do not receive any effec-
tive treatment8-10. Because epilepsy is a complex disease, 
genetic influences as causal factors of the epilepsies can 
point the way to new treatment strategies. On the basis of 
these facts, an elegant study recently reviewed the prog-
ress in this area and suggested specific goals that once ac-
complished promise to lead to cures for epilepsy11. Thus, 
at least 11 genes have now been described for human epi-
lepsy and over 50 more genes have been identified in an-
imal models of epilepsy11-13. Alternatively, the specialists 
believe that the progress in understanding epilepsies of 
complex genetic origin will require not only identification 
of individual susceptibility alleles and analysis of gene to 
gene interactions, but also the study of gene-environ-
ment interactions11. Clinical and experimental evidence 
supports these considerations. To begin with, it has been 
demonstrated that family members of individuals with 
acquired epilepsy are at higher risk of seizures compared 
with the general population11,14,15, and that common genet-
ic features affect kainic acid-induced seizure susceptibili-
ty in rodent models11,16. The individual responsiveness and 
tolerance to antiepileptic drugs are the other important 
consequences of gene-environment interactions in epilep-
sy syndromes11. This topic is supported by a recent study 
demonstrating that the HLA-B*1502 gene could contrib-
ute to the pathogenesis of Stevens-Johnson syndrome and 
toxic epidermal necrolysis in Asian patients, and that ge-
netic susceptibility to carbamazepine-induced cutaneous 
adverse drug reactions is phenotype-specific17. In these 
circumstances, pharmacogenetic approaches to epilepsy 
Figure. Charles Robert Darwin, at the age of 51. He had just published 
his theory of natural selection. From: http://en.wikipedia.org/wiki/
Charles_Darwin.
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are already beginning to produce clinically important res-
olutions in the treatment of patients with epilepsy. For in-
stance, the US Food and Drug Administration (FDA) has re-
cently expanded an alert on the commonly used carbam-
azepine where a newly developed genetic test for risk of 
severe skin reactions is recommended11.
On the whole, despite repeated bouts of illness during 
the last twenty-two years of his life, Darwin still worked 
on his contributions to the evolutionary theory almost 
until his death on April 19, 1882. To date, it is clear that 
Darwin’s thoughts on evolution have influenced many sci-
ence disciplines. An understanding of gene-environment 
interactions and its relevance to the current treatment or 
prevention of chronic diseases, such as epilepsy, is the key 
to what Dr. Charles Darwin called evolutionary science. 
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